Mr Bryant will begin employment with Quidel and join the Quidel board on February 2, 2009. Caren Mason will continue in her current capacity as president and CEO until March 1, 2009, when Mr Bryant’s appointment as president and CEO becomes effective. To facilitate the transition in leadership, Ms Mason will serve as a special advisor until her planned retirement on June 1, 2009.
Most recently, Mr Bryant served as executive vice president and COO at Luminex, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations and commercial operations.
Mark Pulido, chairman of the Quidel board, said: “Doug brings a depth of experience and is a highly respected leader in the worldwide diagnostics industry. Doug’s leadership will enable us to accelerate the momentum built over the last several years as we increase market share of our leading products as well as sharpen our focus on new product and technology opportunities.”